Jump to content

FDA 2019:批准45款新è¯ï¼Œ9æ¬¾ç”Ÿç‰ ç±»ä¼¼è¯-MedSci Cn: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 December 2025

26 November 2025

  • curprev 00:0400:04, 26 November 2025 DellCoughlin40 talk contribs 9,344 bytes +9,344 Created page with "<br><br><br>Acalabrutinib(Calquence)被批准用于治疗成人慢性淋巴细胞白血病或小淋巴细胞性淋巴瘤,lenvatinib(Lenvima)获批与pembrolizumab(Keytruda)联用治疗晚期子宫内膜癌。 2019年,pembrolizumab获得监管机构的审批,增加了六种适应症,包括头颈部鳞状细胞癌和食管癌的一线治疗,获批适应症数量超过20种。 值得注意的是,PARP抑制剂niraparib(Zejula)获得扩展审批,..."